INTI
Inhibitor Therapeutics, Inc.
Key Financials
Net Income
$-3300337
↑ 1.2%
EPS (Diluted)
$-0.02
0.0%
Revenue
$0
NaN%
Total Liabilities
$3.8M
↑ 2.5%
Shareholders' Equity
$-1291912.00
↓ 165.1%
Operating Income
$-3426653
↑ 6.3%
Cash & Equivalents
$2.4M
↓ 57.6%
Total Assets
$2.5M
↓ 55.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/18/2026 | View on SEC |
| DEF 14A | 8/17/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INTI |
| Company Name | Inhibitor Therapeutics, Inc. |
| CIK | 1042418 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (813) 766-2462 |